NorthCrest Asset Manangement LLC Buys 655 Shares of Eli Lilly and Company (NYSE:LLY)

NorthCrest Asset Manangement LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 10.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,846 shares of the company’s stock after purchasing an additional 655 shares during the period. NorthCrest Asset Manangement LLC’s holdings in Eli Lilly and Company were worth $6,065,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of LLY. M&G Plc purchased a new position in shares of Eli Lilly and Company in the first quarter worth about $8,896,000. Virtu Financial LLC purchased a new position in Eli Lilly and Company in the 1st quarter valued at approximately $2,138,000. China Universal Asset Management Co. Ltd. grew its stake in Eli Lilly and Company by 19.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after buying an additional 1,620 shares in the last quarter. Mutual Advisors LLC raised its holdings in Eli Lilly and Company by 404.8% during the 1st quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock valued at $48,699,000 after acquiring an additional 50,197 shares during the period. Finally, Private Advisor Group LLC lifted its position in shares of Eli Lilly and Company by 0.6% during the first quarter. Private Advisor Group LLC now owns 76,282 shares of the company’s stock worth $59,345,000 after acquiring an additional 430 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of several recent research reports. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Bank of America lifted their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a report on Friday, August 9th. Barclays upped their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,025.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, September 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,013.41.

Eli Lilly and Company Trading Up 0.2 %

Shares of LLY stock opened at $892.70 on Friday. The business has a 50-day moving average price of $919.74 and a two-hundred day moving average price of $862.48. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The firm has a market cap of $848.45 billion, a P/E ratio of 109.94, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Equities analysts anticipate that Eli Lilly and Company will post 14.05 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.